Announcement • Mar 18
Liminatus Pharma Inc Announces Planned Phase 1 Clinical Trial of IBA101, A Next-Generation CD47 Blocking Antibody Liminatus announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies. IBA101 is engineered to target the CD47 “don’t-eat-me” signal, a mechanism that enables tumor cells to evade innate immune surveillance. By enhancing macrophage-mediated tumor clearance and antigen presentation, IBA101 is designed to work alongside PD-1/PD-L1 checkpoint inhibitors, which remain the backbone of treatment across multiple solid tumor indications. The planned Phase 1 study is designed as a seamless clinical program, beginning with monotherapy dose escalation to evaluate safety, tolerability, and pharmacokinetics, followed by combination cohorts with PD-1/PD-L1 therapies within the same protocol. This approach is intended to efficiently generate early clinical and translational insights while supporting disciplined dose selection for future development. Lung cancer has been selected as the initial focus of the Phase 1 program, reflecting the widespread use of PD-1/PD-L1 inhibitors in current treatment paradigms and the ongoing need to improve depth and durability of patient responses. The study will incorporate translational analyses aimed at characterizing immune activity and identifying biological features associated with clinical benefit. The company anticipates engaging with regulatory authorities as part of its clinical development planning and is targeting readiness to advance the program following completion of required manufacturing, nonclinical, and regulatory preparation activities. Announcement • Feb 17
Liminatus Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $16.018936 million. Liminatus Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $16.018936 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 13,813,000
Price\Range: $0.29
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 20,719,500
Price\Range: $0.2899
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 20,719,500
Price\Range: $0.2899 Announcement • Feb 11
Liminatus Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $9.999999 million. Liminatus Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $9.999999 million.
Security Name: Common Stock
Security Type: Common Stock
Price\Range: $1.45
Discount Per Security: $0.116
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Price\Range: $1.4499
Discount Per Security: $0.115992
Security Name: Warrants
Security Type: Equity Warrant 
